Myelofibrosis morbidity is driven by splenomegaly, systemic symptoms, and anemia; discontinuation of JAK inhibitors exceeds 30% in part due to cytopenias, underscoring unmet need for better-tolerated ...
The National Institute for Health and Care Excellence (NICE) has recommended fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythemia vera ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results